Prognostic significance of PRAME (preferentially expressed antigen of melanoma) expression in breast cancer
Öz
Purpose: The aim of this study is to detect the PRAME (Preferentially Expressed Antigen of Melanoma) in 54 patients with breast cancer and 37 patients with benign breast lesions.
Materials and Methods: PRAME expressions in 54 breast cancer, 20 benign breast lesions and 10 normal breast tissue samples were studied with RT-PCR. Expression of PRAME was studied with IHC in 37 benign breast lesions, in 54 breast cancer patients from both tumor and normal breast tissue. RT-PCR and IHC results for PRAME were compared in this study.
Results: PRAME was found to be expressed in 50 % of the breast cancer and 25 % of the benign breast lesions. Using IHC method, (+), (++) and (+++) staining for PRAME expression were found in 29,6%, 31,5% and 3,7% of the cases, respectively in invasive component of the breast cancer. PRAME expression detected by both IHC and RT-PCR was compared with prognostic parameters. PRAME expression in breast cancer was found to be associated with high tumor grade and negative hormone receptor. We found an important association between PRAME RT-PCR and of PRAME IHC.
Conclusion: Both RT-PCR in fresh tissues and IHC method in paraffin embedded tissues can be used to identify PRAME expression and the predictive role of PRAME expression.
Anahtar Kelimeler
Kaynakça
- 1. Ikeda H, Lethe B, Lehmann F. Characterization of an antigennthat is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
- 2. Li CM, Guo M,Borczuk A. Gene expression in Wilm’s tumour mimics the earliest committed evre in the metanephric mesenchymal-epithelial transition. AM J Pathol, 2002;160:2181-2190.
- 3. Paydas S, Tanrıverdi K, Yavuz S, Seydaoğlu G. PRAME mRNA levels in cases with chronic leukemia: clanical importance and review of the literature. Leuk Res, 2007;31:365-9.
- 4. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. J. Hematol. 79; 257-261, 2005. 5. Neumann E,Engelsberg A, Decker J. Heterogeneous expression of the tumour -associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell -based immunotherapies? Cancer Res, 2006;58;4090-4095
- 6. Matsushita M, Yamazaki R, Kawakami Y. Quantitative analysis of PRAME for detection of minimal residual disease in leukaemia. Methods Mol Med, 2004;97:267-275.
- 7. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumour-associated antigen PRAME is universally expressed in high-evre neuroblastoma and associated with poor outcome. Clin Cancer Res, 2004;10:4307-4313
- 8. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumour antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell, 2005;122:835-847
- 9. Epping MT, Bernards R. A causal role for the human tumour antigen preferentially expressed antigen of melanoma in cancer. Cancer Res, 2006;66:10639-10642
- 10. Tajeddine N, Gala JL, Louis M. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspaseindependent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res, 2005;65:7348-55.
- 11. Gollner S, Steinbach D, Schenk T, Gruhn B,Zintl F, Ramsay E. Childhood acute myelogenous leukamia: association between PRAME, apoptosis and MDR- reletad gene expression. Eur J Cancer 2006;42:2807-14.
